UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000007696
Receipt No. R000008994
Scientific Title A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.
Date of disclosure of the study information 2012/04/10
Last modified on 2020/04/15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.
Acronym SOAC-1101
Scientific Title A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.
Scientific Title:Acronym SOAC-1101
Region
Japan

Condition
Condition high risk stage II/ stage III colorectal cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the safety and efficacy of UFT/Leucovorin and UFT/Leucovorin/Oxaliplatin in patient with curatively resected high risk stage II/ stage III colorectal cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 3-year desiese free survival rate
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks.
Interventions/Control_2 UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks.
Oxaliplatin gives 85 mg/m2 intravenously on 1,15 day of each course.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Confirmed adenocarcinoma
2) High risk stage II or stage III colorectal cancer
3) Recieved curative resction
4) 20 years old or older
5) PS(ECOG) 0 or 1
6) No previous treatment exclude surgery
7) Oral intake is possible
8) Adequate organ fanction
9) Treatment can start within eight weeks after surgery.
10) Written informed consent
Key exclusion criteria 1) Serious diarrea
2) Serious postoperative complications
3) Serious drug hypersensitivity
4) Pregnant or nursing
5) Serious coexisting illness
1; diabetes mellitus, uncontrolled or controlled with insulin
2; uncontrolled hypertension
3; liver cirrhosis
4; renal disfaunction
5; severe pulmonary dysfunction
6; active infection
7; history of myocardial infarction, unstable angina within 6 months prior to the registration
6) Active synchronous or metachronous malignancy other than carcinoma in situ
7) Sensory neuropathy
8) Severe mental disorders
9) Not suitable for participating in the study for any other reason
Target sample size 200

Research contact person
Name of lead principal investigator
1st name Hisahiro
Middle name
Last name Matsubara
Organization Chiba University Hospital
Division name Esophageal-Gastro-Intestinal Surgery
Zip code 260-8677
Address 1-8-1Inohana, chuo-ku, Chiba-shi, Chiba
TEL 043-226-2109
Email matsuhm@faculty.chiba-u.jp

Public contact
Name of contact person
1st name Hideaki
Middle name
Last name MIyauchi
Organization Chiba surgical oncology development association
Division name The secretariat
Zip code 260-8677
Address 1-8-1 Inohana, Chuo-ku, Chiba, Japan
TEL 043-226-2109
Homepage URL
Email miyahide@faculty.chiba-u.jp

Sponsor
Institute Chiba surgical oncology development association
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Chiba University Certified Clinical Research Review Board
Address 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Chiba
Tel 043-226-2616
Email prc-jim@chiba-u.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 04 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2011 Year 06 Month 01 Day
Date of IRB
2011 Year 06 Month 01 Day
Anticipated trial start date
2011 Year 06 Month 01 Day
Last follow-up date
2020 Year 02 Month 28 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
2021 Year 02 Month 28 Day

Other
Other related information

Management information
Registered date
2012 Year 04 Month 09 Day
Last modified on
2020 Year 04 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008994

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.